John D Markman (John Markman)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Neuropathic Pain

Mass Spectrometry

Top Venues

Journal of neurology

British journal of clinical pharmacology

Pain and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Annina B Schmid, Brigitte Tampin, Ralf Baron, Nanna Brix Finnerup, Per Hansson, Aki Hietaharju, Kika Konstantinou, Chung-Wei Christine Lin, John D Markman, Christine Price, Blair Hamilton Smith, Helen Slater
Recommendations for terminology and the identification of neuropathic pain in people with spine-related leg pain. Outcomes from the NeuPSIG working group. Pain (2023)
John D Markman, Thomas J Schnitzer, Serge Perrot, Said R Beydoun, Seiji Ohtori, Lars Viktrup, Ruoyong Yang, Candace Bramson, Christine R West, Kenneth M Verburg
Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial. Pain and therapy 11 (4) (2022)
Jonathan Mauer, Kristin Bullock, Stephen Watt, Ed Whalen, Leo Russo, Rod Junor, John D Markman, A Brett Hauber, Tommi Tervonen
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis. British journal of clinical pharmacology 88 (8) (2022)
Shin-Ichi Konno, Takuya Nikaido, John D Markman, Makoto Ohta, Toshiya Machida, Naoki Isogawa, Hiroki Yoshimatsu, Lars Viktrup, Mark T Brown, Christine R West, Kenneth M Verburg
Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study. Pain management (2021)
John D Markman, Malca Resnick, Scott Greenberg, Nathaniel Katz, Ruoyong Yang, Joseph Scavone, Ed Whalen, Gabriela Gregorian, Bruce Parsons, Lloyd Knapp
Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of neurology 265 (12) (2018)